Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors

CAMBRIDGE, Mass., Dec. 05, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Jacqualyn “Jackie” Fouse, Ph.D., to its board of directors.

“Through her tenure at Celgene, we had the privilege of working with Jackie and seeing firsthand the value she brings to a growing biotechnology company, so we are thrilled to welcome her to the Agios board of directors,” said David Schenkein, M.D., chief executive officer of Agios. “Jackie’s guidance will be critical as we continue to build a sustainable, research-driven biopharmaceutical company with the goal of making important medicines for patients.” 

Dr. Fouse previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene's board of directors through June 2017. She joined Celgene in 2010 as chief financial officer and was named president of the company's global hematology & oncology franchise in 2014. Before joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as senior vice president, chief financial officer, and head of corporate strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her tenure with Alcon, she held a variety of senior leadership roles with international companies, spending almost a decade of her career in Switzerland. Dr. Fouse earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington.

“The execution across Agios’ research and clinical development programs is remarkable, and I’m pleased to be joining the board during this exciting time as the company prepares to launch their first wholly owned precision medicine,” said Dr. Fouse. “I’ve had the opportunity to help build successful biotechnology companies in my career, including those with leading hematology and oncology franchises, and I look forward to working with the Agios team to apply these learnings as the company continues to grow.”

About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected benefits of Dr. Fouse’s service on the board of directors of Agios and the company's plans for growth and advancement of its programs. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," "possible," "hope," "could," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs, including the risks described under the caption “Risk Factors” included in Agios’ public filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors:
Renee Leck, 617-649-8299
Senior Manager, Investor & Public Relations
[email protected]

Media:
Holly Manning, 617-844-6630
Associate Director, Corporate Communications
[email protected]